Although the initial use of 68Ga-PSMA has significantly improved the evaluation of patients with prostate cancer, 18F-PSMA has practical advantages compared to 68Ga-PSMA, such as a longer half-life (110 min versus 68 min, respectively), minimal urinary excretion, thereby facilitating local tumor detection (by reducing urine-related uptake in the prostatic region), and cyclotron production (avoiding the need for an in-house 68Ga generator). The gene discussed is FOLH1; the disease is neoplasm.